PDL Biopharma (PDLI) 10-K2005 FY Annual report

Filed: 16 Mar 06, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abnormal, ADHF, Advice, affiliated, agonist, alleviate, AmerisourceBergen, andAvastin, andCardura, andDeclomycin, andHuZAF, andHuZAFin, andIsmo, andNeumega, andNuvion, andRaptiva, andRetavase, Andrew, andZamyl, andZenapax, Anglia, aNuvionlaunch, apparent, Asian, augment, Australia, automation, bad, Bedford, Bentley, Berkley, beta, bioequivalent, biopharma, Black, Branch, breakdown, breath, Brewery, bring, Broder, Calcott, capillary, caption, cardiology, CardioPep, Celera, CFO, chargeback, Chicago, Chiron, clause, climate, CNS, CODM, coincided, College, colon, combinedHerceptin, component, conceived, conference, constrictive, contingency, contingent, contra, counterparty, creatinine, critical, cycle, David, decompensated, deposit, deposited, disclaim, distributeRetavase, distributeRetavasein, Divestiture, domicile, doubt, doubtful, DSMB, dyspnea, East, EMEA, endoscopy, esophageal, evolution, excretion, feed, Florida, fluid, forCardene, forecast, forHerceptin, forNuvion, forNuvionfor, forRetavase, fromAvastin, fromCardene, fromRaptiva, Gate, gene, GLYCART, Golden, Guggenhime, hand, hematologic, hemorrhage, hereinafter, HGS, Hospira, hypotension, IfCardene, Immunex, inconsistent, increasedHerceptin, inflammation, intent, inventor, ishttp, Israel, itsAvastin, itsXolair, IVAX, IVBusulfex, IVBusulfextotaled, Iwanicki, jointly, journal, Jue, launchBeneFIX, Lawrence, licensor, liver, lymphoproliferative, manufactureNuvion, manufactureRetavase, Mayo, McKesson, media, Medicament, Metabolism, mg, Michigan, monotherapy, Monsanto, multinational, muscle, myeloma, nameZenapaxin, native, natriuretic, NCI, NDA, ofCardene, ofCardeneIV, ofDeclomycin, ofDeclomycinin, ofDeclomycinto, ofHuZAF, ofNuvion, ofRetavase, ofRetavaseand, ofTysabri, ofXolair, ofZenapax, onceZenapax, onHerceptin, opportunistically, orRetavase, outlicensedZamyl, outlined, outsource, oversee, overstocking, pathology, PCWP, peptide, perception, persuasive, Peter, portal, principle, procedure, proceeding, productsCardeneIV, promoteZenapax, prompt, pulmonary, Reagan, rebate, receiveCardene, recover, Reddy, relaxation, Repligen, Reseller, resubmitted, retreat, retreated, retreatment, Ronald, RTP, sample, Samuel, SAP, scheme, score, sellZenapax, serum, shell, smooth, Society, sodium, speaker, spent, splanchnic, Springfield, SPS, staffing, standstill, steering, stream, strict, subsection, suitable, Sussex, synthetic, terlipressin, terlipresssin, TEVA, thatHuZAF, thatNuvion, thatTysabri, theMorphotek, theNuvion, theRetavase, theRoche, thought, threshold, title, toCardene, toDeclomycin, toRetavase, toRetavaseincluded, toTysabri, toZenapax, trail, transgenic, treasury, trivial, UCB, ularitide, unaudited, unchanged, uncollectible, undisclosed, Union, unissued, Untied, Urology, user, vacant, variceal, vendor, view, VP, wedge, Western, whichCardene, whichRetavase, withNuvion, withTNKase™andActivase, worsening, wrote

Removed: accelerate, allergy, analyzed, animal, assistance, complementarity, composed, confidential, constant, construct, Daniel, declined, Delaware, domain, Ebersole, entity, exploring, flexibility, Fluor, fraud, gaining, genetic, geographical, guide, handle, Hedging, Herceptin, Igeneon, immaterial, insider, launch, logo, McGough, Menlo, myeloid, Mylotarg, observed, panel, paragraph, pathway, prescribed, procurement, project, promissory, promulgated, remission, renovated, serviced, shape, Simulect, SMART, Somerville, strength, structural, substitute, substituted, systemic, temporary, trademark, trust, voluntary, weighted, Zamyl

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PDLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

Mark McDade, Chief Executive Officer, and George T. Jue, Vice President, Finance and Corporate Controller of PDL BioPharma, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

(1) the Annual Report on Form 10-K for the fiscal year ended December 31, 2005 of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

A signed original of this written statement required by Section 906 has been provided to the Securities and Exchange Commission or its staff upon request.

Dated: March 16, 2006

By:

/S/ MARK MCDADE

Mark McDade

Chief Executive Officer

/S/ GEORGE T. JUE

George T. Jue

Vice President, Finance and Corporate Controller

(Principal Accounting Officer)